Centre bans 16 fixed dose combination drugs, including antibiotics, painkillers, skin meds

The Union Health Ministry has imposed a nationwide ban on 16 Fixed Dose Combination (FDC) drugs with immediate effect, prohibiting their manufacture, sale, d...

What Happened

The Union Health Ministry has imposed a nationwide ban on 16 Fixed Dose Combination (FDC) drugs with immediate effect, prohibiting their manufacture, sale, distribution, and supply for human use.
The ban was notified under Section 26A of the Drugs and Cosmetics Act, 1940, following a detailed scientific review by an expert sub-committee constituted under the Drugs Technical Advisory Board (DTAB).
The expert sub-committee submitted its final report in December 2024, concluding that all 16 FDCs lacked adequate therapeutic justification and that their continued availability posed potential health risks to patients.
The banned combinations span multiple therapeutic categories, including antibiotics (e.g., Amoxicillin combined with Serratiopeptidase and Lactobacillus), pain and antispasmodic combinations (e.g., Dicyclomine with Paracetamol and Clidinium Bromide), and dermatological formulations (e.g., multi-ingredient topical skin preparations containing Aloe Extract, Allantoin, Vitamin E, and related compounds).
The action is part of a continuing regulatory effort to rationalise the Indian pharmaceutical market, which has historically carried a large burden of irrational FDC products not approved in most developed-country markets.

Static Topic Bridges

Fixed Dose Combination (FDC) Drugs: Definition and Regulatory Rationale

A Fixed Dose Combination drug is a pharmaceutical formulation that contains two or more active pharmaceutical ingredients combined in a fixed ratio in a single dosage form — a tablet, capsule, syrup, or injection. Rational FDCs simplify treatment regimens, improve patient adherence, reduce pill burden, and lower costs. However, irrational FDCs — where the combination offers no therapeutic advantage over the individual components, or where one component increases harm without benefit — expose patients to unnecessary risk while also contributing to antimicrobial resistance. The World Health Organization (WHO) maintains an Essential Medicines List that distinguishes rational from irrational combinations.

Rational FDC examples: Artemether + Lumefantrine (malaria), Isoniazid + Rifampicin + Pyrazinamide + Ethambutol (tuberculosis), Co-amoxiclav (antibiotic)
Irrational FDC hallmarks: fixed ratios that cannot be individually titrated; components with incompatible pharmacokinetics; no proven synergistic therapeutic benefit; increased adverse effect profile
India has an estimated 35–40% of all FDCs in circulation that lack formal approval or therapeutic justification
WHO Essential Medicines List serves as a global benchmark for rational therapeutics

Connection to this news: The 16 FDCs banned were specifically identified as lacking therapeutic justification, placing them in the irrational category — where banning is a patient safety imperative, not a commercial restriction.

Section 26A of the Drugs and Cosmetics Act, 1940: The Power to Ban

The Drugs and Cosmetics Act, 1940 is the primary legislation governing the import, manufacture, distribution, and sale of drugs and cosmetics in India. Section 26A grants the Central Government the power to prohibit in public interest the manufacture, sale, or distribution of any drug if, after consultation with the Drugs Technical Advisory Board, it is satisfied that such drug is likely to involve any risk to human beings or does not have the therapeutic value claimed for it. This power has been used in several major FDC ban exercises — notably the ban on 344 FDCs in 2016 (subsequently contested in the Supreme Court), the ban on 156 FDCs in 2018, and the 14-FDC ban in 2023.

Drugs and Cosmetics Act, 1940 (as amended): primary law for drug regulation in India
Section 26A: central government's power to prohibit drugs in public interest
Drugs Technical Advisory Board (DTAB): apex statutory body advising the government on drug policy, constituted under Section 5 of the Act
The 2016 ban on 344 FDCs was upheld by the Supreme Court in 2018 (Pfizer Ltd. vs Union of India) after being initially stayed by the Delhi High Court
Schedule H and Schedule H1 drugs carry additional prescription-only restrictions; banned FDCs are removed from market entirely

Connection to this news: The June 2026 ban invokes the same Section 26A authority, following the due process of expert committee review by the DTAB, providing a firm legal basis against challenge.

Central Drugs Standard Control Organisation (CDSCO): India's Drug Regulator

The Central Drugs Standard Control Organisation (CDSCO) is the national regulatory authority for pharmaceuticals and medical devices in India, functioning under the Ministry of Health and Family Welfare. It is headed by the Drugs Controller General of India (DCGI). CDSCO is responsible for approving new drugs, conducting clinical trials, setting quality standards, and coordinating with State Drug Controllers for market surveillance and enforcement. Unlike the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA), CDSCO has historically faced criticism for limited human resources, approval backlogs, and permissive standards for state-level FDC approvals — a loophole that allowed many irrational FDCs to enter the market.

CDSCO headquarters: New Delhi; zonal and sub-zonal offices across India
Drugs Controller General of India (DCGI): administrative head of CDSCO
State Drug Controllers have concurrent jurisdiction over manufacturing licences within their states — a key source of irrational FDC proliferation
Mashelkar Committee (2003) and Ranjit Roy Chaudhury Expert Committee (2014) both recommended rationalisation of India's FDC market
Schedule M of the Drugs and Cosmetics Act sets Good Manufacturing Practice (GMP) standards

Connection to this news: CDSCO and the DTAB expert sub-committee were the bodies that conducted the multi-year technical review leading to the June 2026 ban, illustrating the regulatory process from expert assessment to central government notification.

Antimicrobial Resistance (AMR) and Irrational Antibiotic Use

Antimicrobial resistance (AMR) occurs when microorganisms — bacteria, viruses, fungi, parasites — evolve to resist the effects of drugs, making infections harder to treat and increasing the risk of spread, severe illness, and death. India is one of the largest consumers of antibiotics globally and bears a significant burden of drug-resistant infections. Irrational FDCs that bundle antibiotics with analgesics, probiotics, or enzymes (such as Amoxicillin + Serratiopeptidase + Lactobacillus) contribute to antibiotic overuse and AMR because they are often sold without prescription and the antibacterial component may be unnecessary for the underlying complaint. The National Action Plan on AMR (2017–2021) committed India to reducing unnecessary antibiotic consumption as a key pillar.

India accounts for the highest absolute number of antibiotic-resistant TB cases globally
National Action Plan on AMR 2017–2021: India's framework aligning with WHO Global Action Plan on AMR (2015)
Schedule H1 restrictions (2013): higher-risk antibiotics placed under stricter prescription control and mandatory record-keeping
Serratiopeptidase combined with antibiotics is a common irrational FDC in India — no high-quality evidence supports its adjunct use

Connection to this news: Several of the 16 banned FDCs contain antibiotic components in combination with other drugs, making this ban directly relevant to India's AMR containment effort.

Key Facts & Data

Number of FDCs banned in June 2026: 16
Legal basis: Section 26A, Drugs and Cosmetics Act, 1940
Review body: Expert Sub-Committee under the Drugs Technical Advisory Board (DTAB)
Expert sub-committee's final report: December 28, 2024
Effect: Immediate nationwide prohibition on manufacture, sale, distribution, and supply
Categories banned: antibiotics, antispasmodic-analgesic combinations, dermatological (skin) preparations
Previous major FDC bans: 344 FDCs (2016), 156 FDCs (2018), 14 FDCs (2023)
India's estimated share of irrational FDCs in market: 35–40% of all FDCs
CDSCO is headed by the Drugs Controller General of India (DCGI), under Ministry of Health and Family Welfare